Article Information
History
- October 13, 2023.
Article Versions
- Version 1 (June 20, 2023 - 19:03).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Sandra Bos1,*,#,
- Aaron L. Graber1,#,
- Jaime A. Cardona-Ospina1,
- Elias M. Duarte1,
- Jose Victor Zambrana2,3,
- Jorge A. Ruíz Salinas2,
- Reinaldo Mercado-Hernandez1,
- Tulika Singh1,
- Leah C. Katzelnick4,
- Aravinda de Silva5,
- Guillermina Kuan2,6,
- Angel Balmaseda2,7 and
- Eva Harris1,*
- 1Division of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, Berkeley, CA, USA
- 2Sustainable Sciences Institute, Managua, Nicaragua
- 3Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, MI, USA
- 4Viral Epidemiology and Immunity Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
- 5Department of Microbiology and Immunology, University of North Carolina, Chapel Hill, NC, USA
- 6Centro de Salud Sócrates Flores Vivas, Ministerio de Salud, Managua, Nicaragua
- 7Laboratorio Nacional de Virología, Centro Nacional de Diagnóstico y Referencia, Ministerio de Salud, Managua, Nicaragua
- ↵*Co-corresponding authors, email: eharris{at}berkeley.edu
↵# These authors contributed equally
Posted October 13, 2023.
The association of neutralizing antibodies with protection against symptomatic dengue virus infection varies by serotype, prior infection history, and assay condition
